Citation Report
List of articles citing

In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration

DOI: 10.1038/nature20565
Nature, 2016, 540, 144-149.

#	Paper	IF	Citations
804	Cell-based therapeutic strategies for replacement and preservation in retinal degenerative diseases. **2017**, 58, 1-27		61
803	Protecting retinal ganglion cells. **2017**, 31, 218-224		24
802	Gene therapy approaches for prevention of retinal degeneration in Usher syndrome. **2017**, 24, 68-71		12
801	Interspecies Chimerism with Mammalian Pluripotent Stem Cells. **2017**, 168, 473-486.e15		289
800	Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease. **2017**, 120, 876-894		49
799	Approaches to Reduce CRISPR Off-Target Effects for Safer Genome Editing. **2017**, 22, 7-13		15
798	Practical method for targeted disruption of cilia-related genes by using CRISPR/Cas9-mediated, homology-independent knock-in system. **2017**, 28, 898-906		53
797	CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs. **2017**, 8, 365-378		70
796	Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery. **2017**, 45, e98		54
795	Development and validation of a method for precise dating of female puberty in laboratory rodents: The puberty ovarian maturation score (Pub-Score). **2017**, 7, 46381		26
794	Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9. **2017**, 8, 634-643		64
793	Animal models for neuropsychiatric disorders: prospects for circuit intervention. **2017**, 45, 59-65		11
792	Advances in CRISPR-Cas based genome engineering. **2017**, 1, 78-86		4
791	CRISPR/Cas9 - Mediated Precise Targeted Integration In Vivo Using a Double Cut Donor with Short Homology Arms. **2017**, 20, 19-26		49
790	A lentivirus-free inducible CRISPR-Cas9 system for efficient targeting of human genes. **2017**, 530, 40-49		4
789	Treat the Patient, Not Just the Cell!. **2017**, 120, 1390-1392		2
788	Context-dependent intravital imaging of therapeutic response using intramolecular FRET biosensors. **2017**, 128, 78-94		26

787	Establishment of expanded and streamlined pipeline of PITCh knock-in - a web-based design tool for MMEJ-mediated gene knock-in, PITCh designer, and the variations of PITCh, PITCh-TG and PITCh-KIKO. **2017**, 8, 302-308	19
786	Gene therapy: In vivo gene editing in non-dividing cells. **2017**, 18, 1	6
785	Developmental history and application of CRISPR in human disease. **2017**, 19, e2963	6
784	Application of CRISPR-Cas9 in eye disease. **2017**, 161, 116-123	7
783	Homology-mediated end joining-based targeted integration using CRISPR/Cas9. **2017**, 27, 801-814	165
782	The endlessness evolution of medicine, continuous increase in life expectancy and constant role of the physician. **2017**, 58, 322-330	13
781	Genome editing for human osteoarthritis - a perspective. **2017**, 25, 1195-1198	5
780	A history of genome editing in mammals. **2017**, 28, 237-246	35
779	The contribution of homology arms to nuclease-assisted genome engineering. **2017**, 45, 8105-8115	19
778	Modeling the C9ORF72 repeat expansion mutation using human induced pluripotent stem cells. **2017**, 27, 518-524	8
777	CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy. **2017**, 60, 468-475	17
776	Engineered CRISPR Systems for Next Generation Gene Therapies. **2017**, 6, 1614-1626	24
775	The Hope and Hype of CRISPR-Cas9 Genome Editing: A Review. **2017**, 2, 914-919	30
774	Control of gene editing by manipulation of DNA repair mechanisms. **2017**, 28, 262-274	42
773	Optimizing the DNA Donor Template for Homology-Directed Repair of Double-Strand Breaks. **2017** , 7, 53-60	73
772	Refining strategies to translate genome editing to the clinic. **2017**, 23, 415-423	167
771	Functional interrogation of non-coding DNA through CRISPR genome editing. **2017**, 121-122, 118-129	19
770	Cornerstones of CRISPR-Cas in drug discovery and therapy. **2017**, 16, 89-100	274

769	Genome engineering: NHEJ and CRISPR-Cas9 improve gene therapy. **2016**, 18, 4	3
768	Genome engineering: a new approach to gene therapy for neuromuscular disorders. **2017**, 13, 647-661	45
767	Powerful tools for genetic modification: Advances in gene editing. **2017**, 52, S15-S20	6
766	Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned. **2017**, 21, 574-590	100
765	Complement Depletion Improves Human Red Blood Cell Reconstitution in Immunodeficient Mice. **2017**, 9, 1034-1042	17
764	Ectopic expression of RAD52 and dn53BP1 improves homology-directed repair during CRISPR-Cas9 genome editing. **2017**, 1, 878-888	48
763	Virus-Mediated Genome Editing via Homology-Directed Repair in Mitotic and Postmitotic Cells in Mammalian Brain. **2017**, 96, 755-768.e5	127
762	Magic wands of CRISPR-lots of choices for gene knock-in. **2017**, 33, 501-505	17
761	Beyond editing to writing large genomes. **2017**, 18, 749-760	35
760	Biophysics of Biochemical Signaling in Dendritic Spines: Implications in Synaptic Plasticity. **2017**, 113, 2152-2159	49
759	Single nucleotide editing without DNA cleavage using CRISPR/Cas9-deaminase in the sea urchin embryo. **2017**, 246, 1036-1046	18
758	USH2A Gene Editing Using the CRISPR System. **2017**, 8, 529-541	36
757	Targeted Genome Replacement via Homology-directed Repair in Non-dividing Cardiomyocytes. **2017**, 7, 9363	24
756	Curative approaches for sickle cell disease: A review of allogeneic and autologous strategies. **2017**, 67, 155-168	7
755	CRISPR-based Gene Editing: A Guide for the Clinician. **2017**, 57, 151-164	3
754	In trans paired nicking triggers seamless genome editing without double-stranded DNA cutting. **2017**, 8, 657	51
753	Toward personalized medicine in Bardet-Biedl syndrome. **2017**, 14, 447-456	7
752	Rapidly inducible Cas9 and DSB-ddPCR to probe editing kinetics. **2017**, 14, 891-896	56

751	Xenogeneic chimera-Generated by blastocyst complementation-As a potential unlimited source of recipient-tailored organs. **2017**, 24, e12327	11
750	Generation of Genetically Modified Mice through the Microinjection of Oocytes. **2017**,	8
749	Evaluation of ATM heterozygous mutations underlying individual differences in radiosensitivity using genome editing in human cultured cells. **2017**, 7, 5996	14
748	Epigenetic dysregulation of protocadherins in human disease. **2017**, 69, 172-182	39
747	The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation. **2017**, 24, 481-488	40
746	In□Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation. **2017**, 171, 1495-1507.e15	256
745	Precision genome editing using synthesis-dependent repair of Cas9-induced DNA breaks. **2017**, 114, E10745-E10754	102
744	The pigmented epithelium, a bright partner against photoreceptor degeneration. **2017**, 31, 203-215	10
743	CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice. **2017**, 7, 4159	78
742	Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. **2017**, 20, 1172-1179	482
741	Genetic engineering as a tool for the generation of mouse models to understand disease phenotypes and gene function. **2017**, 48, 228-233	
740	Genome editing: the breakthrough technology for inherited retinal disease?. **2017**, 17, 1245-1254	6
739	A convenient method to pre-screen candidate guide RNAs for CRISPR/Cas9 gene editing by NHEJ-mediated integration of a 'self-cleaving' GFP-expression plasmid. **2017**, 24, 609-621	15
738	Effective gene editing by high-fidelity base editor 2 in mouse zygotes. **2017**, 8, 601-611	57
737	Advances in the delivery of RNA therapeutics: from concept to clinical reality. **2017**, 9, 60	359
736	Progress of stem/progenitor cell-based therapy for retinal degeneration. **2017**, 15, 99	42
735	Sapiens Mitochondrial DNA Genome Circular Long Range Numerical Meta Structures are Highly Correlated with Cancers and Genetic Diseases mtDNA Mutations. **2017**, 09,	8
734	Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. **2017**, 35, 1179-1187	255

733	In Vitro, Ex Vivo and In Vivo Techniques to Study Neuronal Migration in the Developing Cerebral Cortex. **2017**, 7,	10
732	Rodent Models for the Analysis of Tissue Clock Function in Metabolic Rhythms Research. **2017**, 8, 27	19
731	CRISPR/Cas9-Mediated Zebrafish Knock-in as a Novel Strategy to Study Midbrain-Hindbrain Boundary Development. **2017**, 11, 52	21
730	The CRB1 Complex: Following the Trail of Crumbs to a Feasible Gene Therapy Strategy. **2017**, 11, 175	27
729	Visual Prosthesis: Interfacing Stimulating Electrodes with Retinal Neurons to Restore Vision. **2017**, 11, 620	33
728	Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy. **2017**, 2017, 8765154	23
727	The Potential of iPSCs for the Treatment of Premature Aging Disorders. **2017**, 18,	7
726	The Rising Pillar of Genome Engineering: Crispr/Cas9 System Interesting Facts and Challenges in the Development of Gene Therapy. **2017**, 06,	
725	Applications of CRISPR/Cas9 in retinal degenerative diseases. **2017**, 10, 646-651	17
724	Strategies for In Vivo Genome Editing in Nondividing Cells. **2018**, 36, 770-786	36
723	Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/CRISPR-Associated Endonuclease Cas9-Mediated Homology-Independent Integration for Generating Quality Control Materials for Clinical Molecular Genetic Testing. **2018**, 20, 373-380	4
722	The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies. **2018**, 1, e1003	16
721	Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities. **2018**, 171, 207-218	180
720	Small molecules promote CRISPR-Cpf1-mediated genome editing in human pluripotent stem cells. **2018**, 9, 1303	33
719	A Dual-Targeting Delivery System for Effective Genome Editing and In Situ Detecting Related Protein Expression in Edited Cells. **2018**, 19, 2957-2968	29
718	An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome. **2018**, 9, 246-257	44
717	Innovations in CRISPR technology. **2018**, 52, 95-101	14
716	Rice Genome Editing. **2018**, 523-539	1

715 CRISPR-Cas-related technologies in basic and translational liver research. **2018**, 15, 251-252 8

714 Streamlined ex vivo and in vivo genome editing in mouse embryos using recombinant adeno-associated viruses. **2018**, 9, 412 41

713 In Vivo Ovarian Cancer Gene Therapy Using CRISPR-Cas9. **2018**, 29, 223-233 36

712 Hierarchical Design of Tissue Regenerative Constructs. **2018**, 7, e1701067 52

711 Precise and efficient nucleotide substitution near genomic nick via noncanonical homology-directed repair. **2018**, 28, 223-230 29

710 The changing landscape of Lynch syndrome due to PMS2 mutations. **2018**, 94, 61-69 16

709 Development of versatile non-homologous end joining-based knock-in module for genome editing. **2018**, 8, 593 19

708 Development of an Efficient Genome Editing Tool in Bacillus licheniformis Using CRISPR-Cas9 Nickase. **2018**, 84, 47

707 CRISPR/Cas9: the Jedi against the dark empire of diseases. **2018**, 25, 29 14

706 RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors. **2018**, 9, 1674 91

705 Cre-Mediated Transgene Integration in Chinese Hamster Ovary Cells Using Minicircle DNA Vectors. **2018**, 13, e1800063 7

704 Viral Strategies for Targeting the Central and Peripheral Nervous Systems. **2018**, 41, 323-348 74

703 CRISPR Gene Editing in the Kidney. **2018**, 71, 874-883 24

702 A ribonucleoprotein octamer for targeted siRNA delivery. **2018**, 2, 326-337 47

701 Off and back-on again: a tumor suppressor's tale. **2018**, 37, 3058-3069 7

700 Deconstructing the pluripotency gene regulatory network. **2018**, 20, 382-392 40

699 Mouse Embryogenesis. **2018**,

698 Genome Editing During Development Using the CRISPR-Cas Technology. **2018**, 1752, 177-190

697	CRISPR/Cas9-mediated Targeted Integration In Vivo Using a Homology-mediated End Joining-based Strategy. **2018**,	9
696	Inducible Genome Editing with Conditional CRISPR/Cas9 Mice. **2018**, 8, 1627-1635	11
695	Exploration of genetic basis underlying individual differences in radiosensitivity within human populations using genome editing technology. **2018**, 59, ii75-ii82	7
694	CRISPR-engineered genome editing for the next generation neurological disease modeling. **2018**, 81, 459-467	8
693	Gene therapy and editing: Novel potential treatments for neuronal channelopathies. **2018**, 132, 108-117	20
692	Recent Advances in CRISPR-Cas9 Genome Editing Technology for Biological and Biomedical Investigations. **2018**, 119, 81-94	56
691	CRISPR Editing in Biological and Biomedical Investigation. **2018**, 119, 52-61	15
690	Immunity to CRISPR Cas9 and Cas12a therapeutics. **2018**, 10, e1408	66
689	Stem cells and genome editing: approaches to tissue regeneration and regenerative medicine. **2018**, 63, 165-178	13
688	Updated summary of genome editing technology in human cultured cells linked to human genetics studies. **2018**, 63, 133-143	3
687	Long non-coding RNA tagging and expression manipulation via CRISPR/Cas9-mediated targeted insertion. **2018**, 9, 820-825	4
686	Rheostatic Control of Cas9-Mediated DNA Double Strand Break (DSB) Generation and Genome Editing. **2018**, 13, 438-442	8
685	Gene editing & stem cells. **2018**, 17, 10-16	9
684	Emerging Approaches for Spatiotemporal Control of Targeted Genome with Inducible CRISPR-Cas9. **2018**, 90, 429-439	26
683	Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease. **2018**, 39, 49-58	84
682	In vivo genome editing via the HITI method as a tool for gene therapy. **2018**, 63, 157-164	56
681	CRISPR editing in biological and biomedical investigation. **2018**, 233, 3875-3891	15
680	Adaptive hindlimb split-belt treadmill walking in rats by controlling basic muscle activation patterns via phase resetting. **2018**, 8, 17341	10

679 Progress Toward Precise Genetic Repair in Neurons. **2018**, 18, 121-122

678 The road less traveled: strategies to enhance the frequency of homology-directed repair (HDR) for increased efficiency of CRISPR/Cas-mediated transgenesis. **2018**, 51, 437-443 33

677 CRISPR/Cas9 Knockout Strategies to Ablate lncRNA Gene in Cancer Cells. **2018**, 20, 21 25

676 Intra-embryo Gene Cassette Knockin by CRISPR/Cas9-Mediated Genome Editing with Adeno-Associated Viral Vector. **2018**, 9, 286-297 34

675 ARRIGE: Toward a Responsible Use of Genome Editing. **2018**, 115-127

674 CRISPR Craft: DNA Editing the Reconstructive Ladder. **2018**, 142, 1355-1364 16

673 Ribonucleoproteins Mediated Efficient In Vivo Gene Editing in Skin Stem Cells. **2019**, 1879, 75-86 1

672 Predictable and precise template-free CRISPR editing of pathogenic variants. *Nature*, **2018**, 563, 646-651 50.4 250

671 Congenital hypofibrinogenemia associated with R232T. **2018**, 38, 43-48 1

670 Xenotransplantation: Progress Along Paths Uncertain from Models to Application. **2018**, 59, 286-308 8

669 Repairing the Brain: Gene Therapy. **2018**, 8, S123-S130 3

668 New Developments in CRISPR Technology: Improvements in Specificity and Efficiency. **2017**, 18, 1038-1054 9

667 Genetically Encoded Fluorescent Biosensors Illuminate the Spatiotemporal Regulation of Signaling Networks. **2018**, 118, 11707-11794 186

666 Efficient labeling and imaging of protein-coding genes in living cells using CRISPR-Tag. **2018**, 9, 5065 43

665 Revolution in Gene Medicine Therapy and Genome Surgery. **2018**, 9, 17

664 DNA, RNA, and Protein Tools for Editing the Genetic Information in Human Cells. **2018**, 6, 247-263 19

663 Aptamer Chimeras for Therapeutic Delivery: The Challenging Perspectives. **2018**, 9, 15

662 Base editing: precision chemistry on the genome and transcriptome of living cells. **2018**, 19, 770-788 635

661	The Development of an AAV-Based CRISPR SaCas9 Genome Editing System That Can Be Delivered to Neurons and Regulated via Doxycycline and Cre-Recombinase. **2018**, 11, 413	32
660	Quantitative evaluation of incomplete preweaning lethality in mice by using the CRISPR/Cas9 system. **2018**, 8, 16025	1
659	Inherited Retinal Degenerations: Current Landscape and Knowledge Gaps. **2018**, 7, 6	87
658	Functional Genetic Variants Revealed by Massively Parallel Precise Genome Editing. **2018**, 175, 544-557.e16	89
657	All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo. **2018**, 19, 137	58
656	Application of CRISPR/Cas9 technologies combined with iPSCs in the study and treatment of retinal degenerative diseases. **2018**, 137, 679-688	13
655	Increasing the precision of gene editing , and. **2018**, 7, 83-90	5
654	Unraveling of Central Nervous System Disease Mechanisms Using CRISPR Genome Manipulation. **2018**, 10, 1179573518787469	6
653	Adeno-associated virus-mediated delivery of CRISPR-Cas9 for genome editing in the central nervous system. **2018**, 7, 33-41	2
652	Technological advances in integrating multi-kilobase DNA sequences into genomes. **2018**, 7, 16-23	0
651	Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. **2018**, 36, 843-846	348
650	Genetic-Driven Druggable Target Identification and Validation. **2018**, 34, 558-570	25
649	Tild-CRISPR Allows for Efficient and Precise Gene Knockin in Mouse and Human Cells. **2018**, 45, 526-536.e5	76
648	CRISPR/Cas9 mediated targeting of multiple genes in Dictyostelium. **2018**, 8, 8471	35
647	Versatile High-Throughput Fluorescence Assay for Monitoring Cas9 Activity. **2018**, 90, 6913-6921	12
646	In vivo genome editing targeted towards the female reproductive system. **2018**, 41, 898-910	7
645	Genome Editing Redefines Precision Medicine in the Cardiovascular Field. **2018**, 2018, 4136473	7
644	DMSO increases efficiency of genome editing at two non-coding loci. **2018**, 13, e0198637	5

643	Progress in Gene Therapy to Prevent Retinal Ganglion Cell Loss in Glaucoma and Leber's Hereditary Optic Neuropathy. **2018**, 2018, 7108948		22
642	Clinical applications of retinal gene therapies. **2018**, 1, 5-20		9
641	Generation of the Adenovirus Vector-Mediated CRISPR/Cpf1 System and the Application for Primary Human Hepatocytes Prepared from Humanized Mice with Chimeric Liver. **2018**, 41, 1089-1095		8
640	How to create state-of-the-art genetic model systems: strategies for optimal CRISPR-mediated genome editing. **2018**, 46, 6435-6454		22
639	Guiding Lights in Genome Editing for Inherited Retinal Disorders: Implications for Gene and Cell Therapy. **2018**, 2018, 5056279		25
638	CRISPR/Cas9 genome surgery for retinal diseases. **2018**, 28, 23-32		7
637	Myoediting: Toward Prevention of Muscular Dystrophy by Therapeutic Genome Editing. **2018**, 98, 1205-1240		18
636	New Turns for High Efficiency Knock-In of Large DNA in Human Pluripotent Stem Cells. **2018**, 2018, 9465028		5
635	Time Matters: Gene Editing at the Mouse 2-Cell Embryo Stage Boosts Knockin Efficiency. **2018**, 23, 155-157		5
634	CRISPR/Cas9-based genome engineering of zebrafish using a seamless integration strategy. **2018**, 32, 5132-5142		17
633	Reprogramming human T cell function and specificity with non-viral genome targeting. *Nature*, **2018**, 559, 405-409	50.4	367
632	Decoding non-random mutational signatures at Cas9 targeted sites. **2018**, 46, 8417-8434		57
631	Efficient homology-directed gene editing by CRISPR/Cas9 in human stem and primary cells using tube electroporation. **2018**, 8, 11649		34
630	Detection of DNA Double Strand Breaks by H2AX Does Not Result in 53bp1 Recruitment in Mouse Retinal Tissues. **2018**, 12, 286		8
629	Recapitulating X-Linked Juvenile Retinoschisis in Mouse Model by Knock-In Patient-Specific Novel Mutation. **2017**, 10, 453		10
628	SALM/Lrfn Family Synaptic Adhesion Molecules. **2018**, 11, 105		20
627	At the Heart of Genome Editing and Cardiovascular Diseases. **2018**, 123, 221-223		3
626	Seeing the Light after 25 Years of Retinal Gene Therapy. **2018**, 24, 669-681		65

625	Making ends meet: targeted integration of DNA fragments by genome editing. **2018**, 127, 405-420	19
624	Translation of CRISPR Genome Surgery to the Bedside for Retinal Diseases. **2018**, 6, 46	15
623	Applications of CRISPR-Based Genome Editing in the Retina. **2018**, 6, 53	20
622	Genetic therapies for sickle cell disease. **2018**, 55, 76-86	27
621	CRISPR GENOME SURGERY IN THE RETINA IN LIGHT OF OFF-TARGETING. **2018**, 38, 1443-1455	9
620	Targeted Gene Knock Out Using Nuclease-Assisted Vector Integration: Hemi- and Homozygous Deletion of JAG1. **2018**, 1772, 233-248	3
619	Clustered Regularly Interspaced Short Palindromic Repeats-Based Genome Surgery for the Treatment of Autosomal Dominant Retinitis Pigmentosa. **2018**, 125, 1421-1430	65
618	Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9. **2018**, 98, 968-976	20
617	Pompe Disease: From Basic Science to Therapy. **2018**, 15, 928-942	68
616	Biased genome editing using the local accumulation of DSB repair molecules system. **2018**, 9, 3270	15
615	Endogenous HIF2A reporter systems for high-throughput functional screening. **2018**, 8, 12063	0
614	Gene therapy for neurological disorders: progress and prospects. **2018**, 17, 641-659	143
613	iKA-CRISPR hESCs for inducible and multiplex orthogonal gene knockout and activation. **2018**, 592, 2238-2247	4
612	Targeting repair pathways with small molecules increases precise genome editing in pluripotent stem cells. **2018**, 9, 2164	79
611	Practical Recommendations for Improving Efficiency and Accuracy of the CRISPR/Cas9 Genome Editing System. **2018**, 83, 629-642	7
610	From Identification to Function: Current Strategies to Prioritise and Follow-Up GWAS Results. **2018**, 1793, 259-275	0
609	Ocular gene therapy for choroideremia: clinical trials and future perspectives. **2018**, 13, 129-138	10
608	CRISPR therapeutic tools for complex genetic disorders and cancer (Review). **2018**, 53, 443-468	21

607	CRISPR/Cas9 Gene Editing: From Basic Mechanisms to Improved Strategies for Enhanced Genome Engineering In Vivo. **2017**, 17, 263-274	9
606	Alternative Splicing in Genetic Diseases: Improved Diagnosis and Novel Treatment Options. **2018**, 335, 85-141	19
605	Genome editing by natural and engineered CRISPR-associated nucleases. **2018**, 14, 642-651	71
604	Genome editing in the mammalian brain using the CRISPR-Cas system. **2019**, 141, 4-12	14
603	Gene therapy strategies in the treatment of hypertrophic cardiomyopathy. **2019**, 471, 807-815	25
602	Strategies for the Enrichment and Selection of Genetically Modified Cells. **2019**, 37, 56-71	19
601	CRISPR for Neuromuscular Disorders: Gene Editing and Beyond. **2019**, 34, 341-353	9
600	Formulation Strategies for Folate-Targeted Liposomes and Their Biomedical Applications. **2019**, 11,	40
599	Improving Editing Efficiency for the Sequences with NGH PAM Using xCas9-Derived Base Editors. **2019**, 17, 626-635	7
598	Prospects for the Use of Genome-Editing Technology to Correct Neurodegenerative Diseases. **2019**, 9, 154-163	1
597	Niche stiffness underlies the ageing of central nervous system progenitor cells. *Nature*, **2019**, 573, 130-134	144
596	A split CRISPR-Cpf1 platform for inducible genome editing and gene activation. **2019**, 15, 882-888	38
595	Modern Trends in Plant Genome Editing: An Inclusive Review of the CRISPR/Cas9 Toolbox. **2019**, 20,	89
594	A transient reporter for editing enrichment (TREE) in human cells. **2019**, 47, e120	21
593	The Problem of the Low Rates of CRISPR/Cas9-Mediated Knock-ins in Plants: Approaches and Solutions. **2019**, 20,	19
592	CRISPR Craze to Transform Cardiac Biology. **2019**, 25, 791-802	9
591	Advances in gene therapy for cystic fibrosis lung disease. **2019**, 28, R88-R94	33
590	Stabilizing heterochromatin by DGCR8 alleviates senescence and osteoarthritis. **2019**, 10, 3329	41

589	In situ repurposing of dendritic cells with CRISPR/Cas9-based nanomedicine to induce transplant tolerance. **2019**, 217, 119302	34
588	The photoreceptor cilium and its diseases. **2019**, 56, 22-33	21
587	Plug-and-Play Protein Modification Using Homology-Independent Universal Genome Engineering. **2019**, 103, 583-597.e8	32
586	CRISPR Toolbox for Mammalian Cell Engineering. **2019**, 185-206	0
585	. **2019**,	1
584	Lorentz TEM Imaging of Topological Magnetic Features in Asymmetric [Pt/(Co/Ni)M/Ir]N based Multi-Layers. **2019**, 25, 24-25	
583	Using CRISPR/Cas9 to model human liver disease. **2019**, 1, 392-402	10
582	CRISPR-Cas9-mediated therapeutic editing of ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis. **2019**, 5, eaax1210	44
581	Recent advances in the CRISPR genome editing tool set. **2019**, 51, 1-11	67
580	Novel peptides screened by phage display peptide library can mimic epitopes of the FnBPA-A protein and induce protective immunity against Staphylococcus aureus in mice. **2019**, 8, e910	4
579	Fast and cloning-free CRISPR/Cas9-mediated genomic editing in mammalian cells. **2019**, 20, 974-982	6
578	RNA-Guided Recombinase-Cas9 Fusion Targets Genomic DNA Deletion and Integration. **2019**, 2, 209-222	6
577	Precise in vivo genome editing via single homology arm donor mediated intron-targeting gene integration for genetic disease correction. **2019**, 29, 804-819	26
576	Antibody discovery and engineering by enhanced CRISPR-Cas9 integration of variable gene cassette libraries in mammalian cells. **2019**, 11, 1367-1380	17
575	Molecular Therapies for Inherited Retinal Diseases-Current Standing, Opportunities and Challenges. **2019**, 10,	33
574	CRISPR-Cas9-Mediated Genome Editing Increases Lifespan and Improves Motor Deficits in a Huntington's Disease Mouse Model. **2019**, 17, 829-839	41
573	Identification of Glyceraldehyde-3-Phosphate Dehydrogenase Gene as an Alternative Safe Harbor Locus in Pig Genome. **2019**, 10,	4
572	Endogenous Fluorescence Tagging by CRISPR. **2019**, 29, 912-928	23

571	Current Status on Clinical Development of Adeno-Associated Virus-Mediated Liver-Directed Gene Therapy for Inborn Errors of Metabolism. **2019**, 30, 1204-1210	9
570	Applications of CRISPR/Cas9 tools in deciphering the mechanisms of HIV-1 persistence. **2019**, 38, 63-69	4
569	CRISPR technologies for stem cell engineering and regenerative medicine. **2019**, 37, 107447	34
568	Identification of the Sex of Pre-implantation Mouse Embryos Using a Marked Y Chromosome and CRISPR/Cas9. **2019**, 9, 14315	5
567	Principle and Application of Fluorescence Lifetime Imaging for Neuroscience. **2019**, 53-64	3
566	CRISPR-Cas: a tool for cancer research and therapeutics. **2019**, 16, 281-295	83
565	Gene editing in plants: progress and challenges. **2019**, 6, 421-437	102
564	Identification of preexisting adaptive immunity to Cas9 proteins in humans. **2019**, 25, 249-254	374
563	CRISPR-Based Tools in Immunity. **2019**, 37, 571-597	31
562	Adeno-associated virus vector as a platform for gene therapy delivery. **2019**, 18, 358-378	555
561	In vivo proximity proteomics of nascent synapses reveals a novel regulator of cytoskeleton-mediated synaptic maturation. **2019**, 10, 386	44
560	CRISPR/Cas9-Mediated Hitchhike Expression of Functional shRNAs at the Porcine Cluster. **2019**, 8,	3
559	Gene and Base Editing as a Therapeutic Option for Cystic Fibrosis-Learning from Other Diseases. **2019**, 10,	19
558	Editing the Central Nervous System Through CRISPR/Cas9 Systems. **2019**, 12, 110	20
557	Progress and Challenges: Development and Implementation of CRISPR/Cas9 Technology in Filamentous Fungi. **2019**, 17, 761-769	34
556	Emerging gene therapies for cystic fibrosis. **2019**, 13, 709-725	12
555	Plasticity of dendritic spines: Molecular function and dysfunction in neurodevelopmental disorders. **2019**, 73, 541-550	35
554	CRISPR-Cas system: Toward a more efficient technology for genome editing and beyond. **2019**, 120, 16379-16392	39

553	Has retinal gene therapy come of age? From bench to bedside and back to bench. **2019**, 28, R108-R118	28
552	Efficient and flexible tagging of endogenous genes by homology-independent intron targeting. **2019**, 29, 1322-1328	11
551	CRISPR-READI: Efficient Generation of Knockin Mice by CRISPR RNP Electroporation and AAV Donor Infection. **2019**, 27, 3780-3789.e4	39
550	Development of CRISPR-Cas systems for genome editing and beyond. **2019**, 52,	57
549	RNA-guided DNA insertion with CRISPR-associated transposases. **2019**, 365, 48-53	232
548	Orthotopic replacement of T-cell receptor □and □chains with preservation of near-physiological T-cell function. **2019**, 3, 974-984	54
547	Design Approaches for Generating Organ Constructs. **2019**, 24, 877-894	13
546	Genome Editing as a Treatment for the Most Prevalent Causative Genes of Autosomal Dominant Retinitis Pigmentosa. **2019**, 20,	25
545	The next generation of CRISPR-Cas technologies and applications. **2019**, 20, 490-507	498
544	CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing. **2019**, 47, W171-W174	410
543	Evaluation and Reduction of CRISPR Off-Target Cleavage Events. **2019**, 29, 167-174	39
542	CRISPR/Cas9 Delivery Mediated with Hydroxyl-Rich Nanosystems for Gene Editing in Aorta. **2019**, 6, 1900386	14
541	Therapeutic Potential of Wnt and Notch Signaling and Epigenetic Regulation in Mammalian Sensory Hair Cell Regeneration. **2019**, 27, 904-911	30
540	Genome Editing for Duchenne Muscular Dystrophy. **2019**, 383-403	1
539	CRISPR-SONIC: targeted somatic oncogene knock-in enables rapid in vivo cancer modeling. **2019**, 11, 21	4
538	Adeno-Associated Viral Vectors as a Tool for Large Gene Delivery to the Retina. **2019**, 10,	33
537	In vivo genome editing rescues photoreceptor degeneration via a Cas9/RecA-mediated homology-directed repair pathway. **2019**, 5, eaav3335	33
536	Pick a Tag and Explore the Functions of Your Pet Protein. **2019**, 37, 1078-1090	20

535	Exogenous Cytokine-Free Differentiation of Human Pluripotent Stem Cells into Classical Brown Adipocytes. **2019**, 8,		7
534	Establishment of gene-edited pigs expressing human blood-coagulation factor VII and albumin for bioartificial liver use. **2019**, 34, 1851-1859		9
533	Enhanced Cas12a editing in mammalian cells and zebrafish. **2019**, 47, 4169-4180		41
532	A New Class of Medicines through DNA Editing. **2019**, 380, 947-959		100
531	Delivering on the promise of gene editing for cystic fibrosis. **2019**, 6, 97-108		27
530	CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool. **2019**, 8,		20
529	CRISPR/Cas-Mediated Base Editing: Technical Considerations and Practical Applications. **2019**, 37, 1121-1142		158
528	Multiplexed and tunable transcriptional activation by promoter insertion using nuclease-assisted vector integration. **2019**, 47, e67		7
527	Precise therapeutic gene correction by a simple nuclease-induced double-stranded break. *Nature*, **2019**, 568, 561-565	50.4	55
526	Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases. **2019**, 23, 201-222		21
525	CRISPR/Cas9-mediated generic protein tagging in mammalian cells. **2019**, 164-165, 59-66		3
524	Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing. **2019**, 10, 456		43
523	New Human Chromosomal Sites with "Safe Harbor" Potential for Targeted Transgene Insertion. **2019**, 30, 814-828		17
522	Gene therapies in canine models for Duchenne muscular dystrophy. **2019**, 138, 483-489		16
521	Highly Efficient Transgenesis in Ferrets Using CRISPR/Cas9-Mediated Homology-Independent Insertion at the ROSA26 Locus. **2019**, 9, 1971		10
520	Neuron-Specific Genome Modification in the Adult Rat Brain Using CRISPR-Cas9 Transgenic Rats. **2019**, 102, 105-119.e8		34
519	CRISPR/Cas9-mediated endogenous gene tagging in Fusarium oxysporum. **2019**, 126, 17-24		18
518	Creating cell and animal models of human disease by genome editing using CRISPR/Cas9. **2019**, 21, e3082		22

517	Use of AAV Vectors for CRISPR-Mediated In Vivo Genome Editing in the Retina. **2019**, 1950, 123-139	8
516	Beyond classic editing: innovative CRISPR approaches for functional studies of long non-coding RNA. **2019**, 4, bpz017	7
515	New Genetic Approaches to Treating Diseases of the Skin. **2019**, 2301-2309	
514	Gene Therapy in Retinal Dystrophies. **2019**, 20,	45
513	Uncut but Primed for Change. **2019**, 2, 352-354	
512	Advances in genome editing through control of DNA repair pathways. **2019**, 21, 1468-1478	146
511	CRISPR Jumps in New Directions. **2019**, 2, 354-356	
510	HMEJ-mediated efficient site-specific gene integration in chicken cells. **2019**, 13, 90	8
509	Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse. **2019**, 20, 276	23
508	CRISPR: a promising tool for lipid physiology and therapeutics. **2019**, 30, 172-176	4
507	CRISPR-Cas3 induces broad and unidirectional genome editing in human cells. **2019**, 10, 5302	66
506	Genetic Modification of Brain Organoids. **2019**, 13, 558	14
505	Gene therapy for visual loss: Opportunities and concerns. **2019**, 68, 31-53	46
504	Basic and Clinical Application of Adeno-Associated Virus-Mediated Genome Editing. **2019**, 30, 673-681	4
503	Ways of improving precise knock-in by genome-editing technologies. **2019**, 138, 1-19	21
502	Homology-independent genome integration enables rapid library construction for enzyme expression and pathway optimization in Yarrowia lipolytica. **2019**, 116, 354-363	24
501	Long-Term Effects of In Vivo Genome Editing in the Mouse Retina Using Campylobacter jejuni Cas9 Expressed via Adeno-Associated Virus. **2019**, 27, 130-136	32
500	FOXO3-Engineered Human ESC-Derived Vascular Cells Promote Vascular Protection and Regeneration. **2019**, 24, 447-461.e8	39

499	Plant DNA Repair Pathways and Their Applications in Genome Engineering. **2019**, 1917, 3-24	7
498	CRISPR-DT: designing gRNAs for the CRISPR-Cpf1 system with improved target efficiency and specificity. **2019**, 35, 2783-2789	29
497	Material solutions for delivery of CRISPR/Cas-based genome editing tools: Current status and future outlook. **2019**, 26, 40-66	58
496	CRISPR Correction of Duchenne Muscular Dystrophy. **2019**, 70, 239-255	78
495	Creating Genetically Modified Marmosets. **2019**, 335-353	3
494	Harnessing genomic information for livestock improvement. **2019**, 20, 135-156	128
493	Non-Viral Delivery To Enable Genome Editing. **2019**, 37, 281-293	62
492	Quantitative Rodent Brain Receptor Imaging. **2020**, 22, 223-244	13
491	Genome editing-based approaches for imaging protein localization and dynamics in the mammalian brain. **2020**, 150, 2-7	4
490	Tailored chromatin modulation to promote tissue regeneration. **2020**, 97, 3-15	5
489	Rescue of premature aging defects in Cockayne syndrome stem cells by CRISPR/Cas9-mediated gene correction. **2020**, 11, 1-22	29
488	Kidney organoids in translational medicine: Disease modeling and regenerative medicine. **2020**, 249, 34-45	23
487	Advances in gene therapy for hemophilia: basis, current status, and future perspectives. **2020**, 111, 31-41	19
486	Targeted knock-in into the OVA locus of chicken cells using CRISPR/Cas9 system with homology-independent targeted integration. **2020**, 129, 363-370	2
485	Understanding the role of calcium-mediated cell death in high-frequency irreversible electroporation. **2020**, 131, 107369	20
484	Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. **2020**, 5, 1	579
483	Gene Knock-Ins in Using Homology-Independent Insertion of Universal Donor Plasmids. **2020**, 214, 75-89	12
482	Sharpening the Molecular Scissors: Advances in Gene-Editing Technology. **2020**, 23, 100789	58

481	Cas12a mediates efficient and precise endogenous gene tagging via MITI: microhomology-dependent targeted integrations. **2020**, 77, 3875-3884	10
480	New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells. **2020**, 28, 480-490	10
479	Genome Editing in Patient iPSCs Corrects the Most Prevalent Mutations and Reveals Intriguing Mutant mRNA Expression Profiles. **2020**, 17, 156-173	35
478	Ex Vivo/In vivo Gene Editing in Hepatocytes Using "All-in-One" CRISPR-Adeno-Associated Virus Vectors with a Self-Linearizing Repair Template. **2020**, 23, 100764	16
477	Recent advances in CRISPR/Cas9-mediated knock-ins in mammalian cells. **2020**, 308, 1-9	23
476	Gene editing prospects for treating inherited retinal diseases. **2020**, 57, 437-444	11
475	An Improved CRISPR/dCas9 Interference Tool for Neuronal Gene Suppression. **2020**, 2, 9	4
474	CHO Cell Line Development and Engineering via Site-specific Integration: Challenges and Opportunities. **2020**, 25, 633-645	6
473	Synthetic regulation of multicellular systems for regenerative engineering. **2020**, 16, 42-51	1
472	Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa. **2020**, 28, 2139-2149	8
471	Enhancing site-specific DNA integration by a Cas9 nuclease fused with a DNA donor-binding domain. **2020**, 48, 10590-10601	10
470	Transmembrane protein 45A regulates the proliferation, migration, and invasion of glioma cells through nuclear factor kappa-B. **2020**, 31, 900-907	2
469	AMPA receptor trafficking in the developing and mature glutamatergic synapse. **2020**, 507-525	
468	Genome Editing for CNS Disorders. **2020**, 14, 579062	5
467	Caspase-7 deficiency in Chinese hamster ovary cells reduces cell proliferation and viability. **2020**, 53, 52	2
466	Aspects of Gene Therapy Products Using Current Genome-Editing Technology in Japan. **2020**, 31, 1043-1053	3
465	Correction of Airway Stem Cells: Genome Editing Approaches for the Treatment of Cystic Fibrosis. **2020**, 31, 956-972	6
464	Yeast Cell wall Particle mediated Nanotube-RNA delivery system loaded with miR365 Antagomir for Post-traumatic Osteoarthritis Therapy via Oral Route. **2020**, 10, 8479-8493	10

463	An effective vaginal gel to deliver CRISPR/Cas9 system encapsulated in poly (□amino ester) nanoparticles for vaginal gene therapy. **2020**, 58, 102897	7
462	Inhibitors of DNA double-strand break repair at the crossroads of cancer therapy and genome editing. **2020**, 182, 114195	5
461	Dendritic Spine Plasticity: Function and Mechanisms. **2020**, 12, 36	25
460	Harnessing endogenous repair mechanisms for targeted gene knock-in of bovine embryos. **2020**, 10, 16031	5
459	Modulation of DNA double-strand break repair as a strategy to improve precise genome editing. **2020**, 39, 6393-6405	19
458	A non-viral genome editing platform for site-specific insertion of large transgenes. **2020**, 11, 380	1
457	Adeno-associated virus-mediated gene delivery promotes S-phase entry-independent precise targeted integration in cardiomyocytes. **2020**, 10, 15348	10
456	Intron with transgenic marker (InTraM) facilitates high-throughput screening of endogenous gene reporter lines. **2020**, 58, e23391	
455	Synthetic Virus-Derived Nanosystems (SVNs) for Delivery and Precision Docking of Large Multifunctional DNA Circuitry in Mammalian Cells. **2020**, 12,	6
454	Genome editing with the donor plasmid equipped with synthetic crRNA-target sequence. **2020**, 10, 14120	0
453	Use of Customizable Nucleases for Gene Editing and Other Novel Applications. **2020**, 11,	5
452	Suppression of Improves In Vitro and In Vivo Gene Integration by Promoting Homology-Directed Repair. **2020**, 21,	3
451	Novel Therapeutic Approaches for the Treatment of Retinal Degenerative Diseases: Focus on CRISPR/Cas-Based Gene Editing. **2020**, 14, 838	8
450	Methods Favoring Homology-Directed Repair Choice in Response to CRISPR/Cas9 Induced-Double Strand Breaks. **2020**, 21,	27
449	Methodologies and Challenges for CRISPR/Cas9 Mediated Genome Editing of the Mammalian Brain. **2020**, 2, 602970	7
448	Viral Vectors as Gene Therapy Agents for Treatment of Glioblastoma. **2020**, 12,	3
447	Targeted Protein Degradation Phenotypic Studies Using HaloTag CRISPR/Cas9 Endogenous Tagging Coupled with HaloPROTAC3. **2020**, 91, e81	5
446	A Simple and Efficient CRISPR Technique for Protein Tagging. **2020**, 9,	1

445	LncRNAs in Cancer: From garbage to Junk. **2020**, 12,	16
444	A CRISPR-Cas9, Cre-, and Flp- Cascade Strategy for the Precise and Efficient Integration of Exogenous DNA into Cellular Genomes. **2020**, 3, 470-486	2
443	CRISPR-Cas Tools and Their Application in Genetic Engineering of Human Stem Cells and Organoids. **2020**, 27, 705-731	29
442	NT-4 attenuates neuroinflammation via TrkB/PI3K/FoxO1 pathway after germinal matrix hemorrhage in neonatal rats. **2020**, 17, 158	15
441	ZKSCAN3 counteracts cellular senescence by stabilizing heterochromatin. **2020**, 48, 6001-6018	19
440	Diurnal Control of Blood Pressure Is Uncoupled From Sodium Excretion. **2020**, 75, 1624-1634	11
439	Pipeline for the Generation and Characterization of Transgenic Human Pluripotent Stem Cells Using the CRISPR/Cas9 Technology. **2020**, 9,	4
438	Improving Precise CRISPR Genome Editing by Small Molecules: Is there a Magic Potion?. **2020**, 9,	17
437	Knockout of cytidine monophosphate-N-acetylneuraminic acid hydroxylase in Chinese hamster ovary cells by CRISPR/Cas9-based gene-editing technology. **2020**, 161, 107663	5
436	Retinal Dystrophies and the Road to Treatment: Clinical Requirements and Considerations. **2020**, 9, 159-179	9
435	Valproic Acid Significantly Improves CRISPR/Cas9-Mediated Gene Editing. **2020**, 9,	4
434	Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. **2020**, 38, 824-844	466
433	Development of Cellular Models to Study Efficiency and Safety of Gene Edition by Homologous Directed Recombination Using the CRISPR/Cas9 System. **2020**, 9,	0
432	Development of Highly Efficient Dual-AAV Split Adenosine Base Editor for In Vivo Gene Therapy. **2020**, 4, 2000309	12
431	Recent Advances in CRISPR/Cas9 Delivery Strategies. **2020**, 10,	53
430	Gene Therapy for Cystic Fibrosis: Progress and Challenges of Genome Editing. **2020**, 21,	15
429	Animal Models of Cardiomyopathies. **2020**,	1
428	SIRT7 antagonizes human stem cell aging as a heterochromatin stabilizer. **2020**, 11, 483-504	37

427	Orthotopic T-Cell Receptor Replacement-An "Enabler" for TCR-Based Therapies. **2020**, 9,	9
426	A Site-Specific Integration Reporter System That Enables Rapid Evaluation of CRISPR/Cas9-Mediated Genome Editing Strategies in CHO Cells. **2020**, 15, e2000057	0
425	Various strategies of effector accumulation to improve the efficiency of genome editing and derivative methodologies. **2020**, 56, 359-366	4
424	In Vivo Genome Engineering for the Treatment of Muscular Dystrophies. **2020**, 6, 52-66	
423	The evolutionary origin of developmental enhancers in vertebrates: Insights from non-model species. **2020**, 62, 326-333	3
422	In vivo CRISPRa decreases seizures and rescues cognitive deficits in a rodent model of epilepsy. **2020**, 143, 891-905	40
421	Overcoming bottlenecks in plant gene editing. **2020**, 54, 79-84	50
420	Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing. **2020**, 98, 615-632	31
419	Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. **2020**, 368, 290-296	325
418	RS-1 enhances CRISPR-mediated targeted knock-in in bovine embryos. **2020**, 87, 542-549	11
417	Metabolic and Redox Signaling of the Nucleoredoxin-Like-1 Gene for the Treatment of Genetic Retinal Diseases. **2020**, 21,	11
416	The therapeutic potential of exogenous adult stem cells for the injured central nervous system. **2020**, 147-258	1
415	The Histone Chaperone FACT Induces Cas9 Multi-turnover Behavior and Modifies Genome Manipulation in Human Cells. **2020**, 79, 221-233.e5	12
414	The delivery challenge: fulfilling the promise of therapeutic genome editing. **2020**, 38, 845-855	69
413	Volume Microscopy. **2020**,	
412	Mechanisms of axon polarization in pyramidal neurons. **2020**, 107, 103522	1
411	Direct Readout of Neural Stem Cell Transgenesis with an Integration-Coupled Gene Expression Switch. **2020**, 107, 617-630.e6	10
410	Current trends in gene recovery mediated by the CRISPR-Cas system. **2020**, 52, 1016-1027	14

409	Poly(Beta-Amino Ester) Nanoparticles Enable Nonviral Delivery of CRISPR-Cas9 Plasmids for Gene Knockout and Gene Deletion. **2020**, 20, 661-672	17
408	Cell-cell contact-induced gene editing/activation in mammalian cells using a synNotch-CRISPR/Cas9 system. **2020**, 11, 299-303	7
407	CRISPR-Cas12a: Functional overview and applications. **2020**, 43, 8-17	46
406	Characterisation of endogenous Claudin-1 expression, motility and susceptibility to hepatitis C virus in CRISPR knock-in cells. **2020**, 112, 140-151	2
405	Fast and efficient generation of knock-in human organoids using homology-independent CRISPR-Cas9 precision genome editing. **2020**, 22, 321-331	87
404	Microtubule Minus-End Binding Protein CAMSAP2 and Kinesin-14 Motor KIFC3 Control Dendritic Microtubule Organization. **2020**, 30, 899-908.e6	14
403	The rapidly advancing Class 2 CRISPR-Cas technologies: A customizable toolbox for molecular manipulations. **2020**, 24, 3256-3270	22
402	A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency. **2020**, 6, eaax5701	21
401	Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy. **2020**, 19, 175-182	33
400	Single AAV-mediated mutation replacement genome editing in limited number of photoreceptors restores vision in mice. **2020**, 11, 482	17
399	Genome Editing for the Understanding and Treatment of Inherited Cardiomyopathies. **2020**, 21,	9
398	RNA editing as a therapeutic approach for retinal gene therapy requiring long coding sequences. **2020**, 21,	33
397	Challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy. **2020**, 15, e0228072	12
396	Efficient and risk-reduced genome editing using double nicks enhanced by bacterial recombination factors in multiple species. **2020**, 48, e57	1
395	CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors. **2020**, 181, 136-150	137
394	A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I. **2020**, 28, 1442-1454	19
393	Methodological approaches to understand the molecular mechanism of structural plasticity of dendritic spines. **2021**, 54, 6902-6911	2
392	In Vivo CRISPR/Cas9-Mediated Genome Editing Mitigates Photoreceptor Degeneration in a Mouse Model of X-Linked Retinitis Pigmentosa. **2020**, 61, 31	12

391	Correcting visual loss by genetics and prosthetics. **2020**, 16, 1-7	1
390	Dual Supramolecular Nanoparticle Vectors Enable CRISPR/Cas9-Mediated Knockin of Retinoschisin 1 Gene-A Potential Nonviral Therapeutic Solution for X-Linked Juvenile Retinoschisis. **2020**, 7, 1903432	17
389	ORANGE: A CRISPR/Cas9-based genome editing toolbox for epitope tagging of endogenous proteins in neurons. **2020**, 18, e3000665	48
388	Neuroprotective Strategies for Retinal Ganglion Cell Degeneration: Current Status and Challenges Ahead. **2020**, 21,	34
387	CRISPR Interference-Potential Application in Retinal Disease. **2020**, 21,	12
386	Clinical Genetics and Genomics of Aging. **2020**,	1
385	Efficient production of large deletion and gene fragment knock-in mice mediated by genome editing with Cas9-mouse Cdt1 in mouse zygotes. **2021**, 191, 23-31	5
384	Retinal gene therapy: an eye-opener of the 21st century. **2021**, 28, 209-216	7
383	Combi-CRISPR: combination of NHEJ and HDR provides efficient and precise plasmid-based knock-ins in mice and rats. **2021**, 140, 277-287	8
382	Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases. **2021**, 168, 181-195	6
381	Therapeutic genome editing in cardiovascular diseases. **2021**, 168, 147-157	6
380	Bi-FoRe: an efficient bidirectional knockin strategy to generate pairwise conditional alleles with fluorescent indicators. **2021**, 12, 39-56	2
379	Imaging dendritic spines: molecular organization and signaling for plasticity. **2021**, 67, 66-74	4
378	Non-viral strategies for delivering genome editing enzymes. **2021**, 168, 99-117	20
377	Rod photoreceptor clearance due to misfolded rhodopsin is linked to a DAMP-immune checkpoint switch. **2021**, 296, 100102	1
376	Revisiting gene delivery to the brain: silencing and editing. **2021**, 9, 1065-1087	5
375	Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing. **2021**, 11, 614-648	66
374	Establishment of human fetal hepatocyte organoids and CRISPR-Cas9-based gene knockin and knockout in organoid cultures from human liver. **2021**, 16, 182-217	24

373	Genome editing in human hematopoietic stem and progenitor cells via CRISPR-Cas9-mediated homology-independent targeted integration. **2021**, 29, 1611-1624	5
372	Current Status of and Perspectives on the Application of Marmosets in Neurobiology. **2021**, 44, 27-48	15
371	Quantification of Cellular Drug Biodistribution Addresses Challenges in Evaluating and Encapsulated Drug Delivery. **2021**, 4, 2000125	2
370	Recent advances in gene therapy for neurodevelopmental disorders with epilepsy. **2021**, 157, 229-262	12
369	A hypomorphic variant in EYS detected by genome-wide association study contributes toward retinitis pigmentosa. **2021**, 4, 140	1
368	Targeted Knock-in of Transgenes into the CHO Cell Genome Using CRISPR-mediated Integration Systems. **2021**, 333, 07001	1
367	Novel mutation in autosomal recessive bestrophinopathy in Japanese siblings. **2021**, 11, 71-76	1
366	Optimization and Validation of CAR Transduction into Human Primary NK Cells Using CRISPR and AAV.	1
365	CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals. **2021**, 181, 185-229	2
364	Generation of Mouse Model (KI and CKO) via Easi-CRISPR. **2021**, 2224, 1-27	4
363	Genetic glycoengineering in mammalian cells. **2021**, 296, 100448	18
362	CRISPR genome engineering for retinal diseases. **2021**, 182, 29-79	5
361	CRISPR-mediated Labeling of Cells in Chick Embryos Based on Selectively Expressed Genes. **2021**, 11, e4105	0
360	Genome Editing to Develop Disease Resistance in Crops. **2021**, 224-252	0
359	Knock-in of Labeled Proteins into 5'UTR Enables Highly Efficient Generation of Stable Cell Lines. **2021**, 46, 21-35	1
358	Epigenetic silencing directs expression heterogeneity of stably integrated multi-transcript unit genetic circuits. **2021**, 11, 2424	2
357	CRISPR/dCas9 as a Therapeutic Approach for Neurodevelopmental Disorders: Innovations and Limitations Compared to Traditional Strategies. **2021**, 43, 253-261	2
356	CRISPR-Cas9 in cancer therapeutics. **2021**, 181, 129-163	1

355	Approach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect. **2021**, 78, 2683-2708	14
354	Using CRISPR-Cas9-based genome engineering tools in Drosophila melanogaster. **2021**, 180, 85-121	
353	Gene editing and modulation for Duchenne muscular dystrophy. **2021**, 182, 225-255	3
352	A homology independent sequence replacement strategy in human cells using a CRISPR nuclease. **2021**, 11, 200283	2
351	Application of CRISPR-Cas systems in neuroscience. **2021**, 178, 231-264	2
350	Safe harbor-targeted CRISPR-Cas9 homology-independent targeted integration for multimodality reporter gene-based cell tracking. **2021**, 7,	3
349	Universal toxin-based selection for precise genome engineering in human cells. **2021**, 12, 497	12
348	Targeted Gene Delivery: Where to Land. **2020**, 2, 609650	3
347	Efficient Human Cell Coexpression System and Its Application to the Production of Multiple Coronavirus Antigens. **2021**, 5, e2000154	1
346	One-step generation of a targeted knock-in calf using the CRISPR-Cas9 system in bovine zygotes. **2021**, 22, 118	7
345	Gene Correction Recovers Phagocytosis in Retinal Pigment Epithelium Derived from Retinitis Pigmentosa-Human-Induced Pluripotent Stem Cells. **2021**, 22,	6
344	Evolving AAV-delivered therapeutics towards ultimate cures. **2021**, 99, 593-617	9
343	Breaking Boundaries in the Brain-Advances in Editing Tools for Neurogenetic Disorders. **2021**, 3, 623519	
342	Advances and Obstacles in Homology-Mediated Gene Editing of Hematopoietic Stem Cells. **2021**, 10,	4
341	Genome Editing Therapeutic Approaches for Neurological Disorders: Where Are We in the Translational Pipeline?. **2021**, 15, 632522	4
340	A CRISPR/Cas9-Mediated, Homology-Independent Tool Developed for Targeted Genome Integration in Yarrowia lipolytica. **2021**, 87,	11
339	Expanding the Potential of Mammalian Genome Engineering Targeted DNA Integration. **2021**, 10, 429-446	1
338	CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases. **2021**, 29, 571-586	37

337	CRISPR/Cas9 gene editing therapies for cystic fibrosis. **2021**, 21, 767-780	2
336	Molecular classification of zebrafish retinal ganglion cells links genes to cell types to behavior. **2021**, 109, 645-662.e9	22
335	CRISPR-Targeted CAR Gene Insertion Using Cas9/RNP and AAV6 Enhances Anti-AML Activity of Primary NK Cells.	4
334	Amelioration of hemophilia B through CRISPR/Cas9 induced homology-independent targeted integration.	1
333	Genome-Editing Strategies for Treating Human Retinal Degenerations. **2021**, 32, 247-259	8
332	CRISPR/Cas-Dependent and Nuclease-Free Therapeutic Gene Editing. **2021**, 32, 275-293	8
331	Analysis of Pathogenic Variants Correctable With CRISPR Base Editing Among Patients With Recessive Inherited Retinal Degeneration. **2021**, 139, 319-328	12
330	An optimized CRISPR/Cas9 approach for precise genome editing in neurons. **2021**, 10,	11
329	Non-viral genome-editing in mouse bona fide hematopoietic stem cells with CRISPR/Cas9. **2021**, 20, 451-462	2
328	Advanced imaging and labelling methods to decipher brain cell organization and function. **2021**, 22, 237-255	28
327	Inducing lateralized phosphenes over the occipital lobe using transcranial magnetic stimulation to navigate a virtual environment. **2021**, 16, e0249996	
326	Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice. **2021**, 12, 2121	45
325	A HIT-trapping strategy for rapid generation of reversible and conditional alleles using a universal donor. **2021**, 31, 900-909	0
324	Co-opting regulation bypass repair as a gene-correction strategy for monogenic diseases. **2021**, 29, 3274-3292	1
323	Chromosome-level genome reference and genome editing of the tea geometrid. **2021**, 21, 2034-2049	4
322	Electroporation-Mediated Genome Editing of Livestock Zygotes. **2021**, 12, 648482	7
321	Distinct in vivo dynamics of excitatory synapses onto cortical pyramidal neurons and inhibitory interneurons.	0
320	Addressing the dark matter of gene therapy: technical and ethical barriers to clinical application. **2021**, 1	1

319	The Z-Disk Final Common Pathway in Cardiomyopathies.	1
318	CRISPR Genome Editing Made Easy Through the CHOPCHOP Website. **2021**, 1, e46	5
317	Comparative Analysis of Patient-Matched PDOs Revealed a Reduction in OLFM4-Associated Clusters in Metastatic Lesions in Colorectal Cancer. **2021**, 16, 954-967	4
316	Somatic genetics analysis of sleep in adult mice.	0
315	CRISPR Screens in Toxicology Research: An Overview. **2021**, 1, e136	2
314	Early and late stage gene therapy interventions for inherited retinal degenerations. **2021**, 86, 100975	18
313	CRISPR-Based Genome Editing as a New Therapeutic Tool in Retinal Diseases. **2021**, 63, 768-779	0
312	Efficient biallelic knock-in in mouse embryonic stem cells by in vivo-linearization of donor and transient inhibition of DNA Polymerase Ø DNA-PK.	0
311	Homology-based repair induced by CRISPR-Cas nucleases in mammalian embryo genome editing. **2021**, 1	3
310	Single-cell transcriptome analysis defines heterogeneity of the murine pancreatic ductal tree. **2021**, 10,	7
309	In vivo gene editing via homology-independent targeted integration for adrenoleukodystrophy treatment. **2021**,	1
308	Streamlined Human Cell-Based Recombinase-Mediated Cassette Exchange Platform Enables Multigene Expression for the Production of Therapeutic Proteins. **2021**, 10, 1715-1727	0
307	A cleavage-based surrogate reporter for the evaluation of CRISPR-Cas9 cleavage efficiency. **2021**, 49, e85	1
306	High-fidelity, efficient, and reversible labeling of endogenous proteins using CRISPR-based designer exon insertion. **2021**, 10,	4
305	Exploiting DNA Endonucleases to Advance Mechanisms of DNA Repair. **2021**, 10,	1
304	Analysis of NHEJ-Based DNA Repair after CRISPR-Mediated DNA Cleavage. **2021**, 22,	2
303	Identification of cis-HOX-HOXC10 axis as a therapeutic target for colorectal tumor-initiating cells without APC mutations. **2021**, 36, 109431	3
302	Targeted mutagenesis in human iPSCs using CRISPR genome-editing tools. **2021**, 191, 44-58	1

301	IgSF11 homophilic adhesion proteins promote layer-specific synaptic assembly of the cortical interneuron subtype. **2021**, 7,	5
300	Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. **2021**, 4, 179-191	5
299	Cav1.4 dysfunction and congenital stationary night blindness type 2. **2021**, 473, 1437-1454	5
298	Gene therapy for Fabry disease: Progress, challenges, and outlooks on gene-editing. **2021**, 134, 117-131	3
297	Targeted CRISPR-Cas9-based gene knockouts in the model brown alga Ectocarpus. **2021**, 231, 2077-2091	7
296	Gene Editing and Modulation: the Holy Grail for the Genetic Epilepsies?. **2021**, 18, 1515-1523	0
295	The method of choice to knock-in large inserts via CRISPR.	0
294	RIPK1 regulates cell function and death mediated by UVB radiation and TNF- **2021**, 135, 304-311	2
293	Tissue specificity of DNA repair: the CRISPR compass. **2021**, 37, 958-962	2
292	delivery of CRISPR-Cas9 therapeutics: Progress and challenges. **2021**, 11, 2150-2171	17
291	Recent advancements in CRISPR-Cas toolbox for imaging applications. **2021**, 1-24	3
290	CRISPR/Cas9-Mediated Genetic Correction in a Mouse Model of Hemophilia A. **2021**, 9, 672564	2
289	Harnessing DSB repair to promote efficient homology-dependent and -independent prime editing.	
288	CRISPR/Cas9 mediated somatic gene therapy for insertional mutations: the vibrator mouse model. **2021**, 4, 168-175	0
287	Embryo-Engineered Nonhuman Primate Models: Progress and Gap to Translational Medicine. **2021**, 2021, 9898769	0
286	Efficient single copy integration via homology-directed repair (scHDR) by 5'modification of large DNA donor fragments in mice.	
285	Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy. **2021**, 29, 3243-3257	3
284	Synaptotagmin 7 is targeted to the axonal plasma membrane through ecretase processing to promote synaptic vesicle docking in mouse hippocampal neurons. **2021**, 10,	4

283	In vivo somatic cell base editing and prime editing. **2021**, 29, 3107-3124	20
282	CRISPR-Cas12a induced DNA double-strand breaks are repaired by locus-dependent and error-prone pathways in a fungal pathogen.	0
281	Nanometer-Scale Imaging of Compartment-Specific Localization and Dynamics of Voltage-Gated Sodium Channels.	0
280	Fast and reliable sgRNA efficiency testing using HIReff.	
279	Points of View on the Tools for Genome/Gene Editing. **2021**, 22,	2
278	Efficient biallelic knock-in in mouse embryonic stem cells by in vivo-linearization of donor and transient inhibition of DNA polymerase /DNA-PK. **2021**, 11, 18132	0
277	Genome edited B cells: a new frontier in immune cell therapies. **2021**, 29, 3192-3204	0
276	Myc determines the functional age state of oligodendrocyte progenitor cells. **2021**, 1, 826-837	0
275	Toward the Treatment of Inherited Diseases of the Retina Using CRISPR-Based Gene Editing. **2021**, 8, 698521	1
274	CRISPR/Cas correction of muscular dystrophies. **2021**, 408, 112844	1
273	A protocol for efficient CRISPR-Cas9-mediated knock-in in colorectal cancer patient-derived organoids. **2021**, 2, 100780	1
272	Comparison of promoter, DNA vector, and cationic carrier for efficient transfection of hMSCs from multiple donors and tissue sources. **2021**, 26, 81-93	0
271	Improvements in Gene Editing Technology Boost Its Applications in Livestock. **2020**, 11, 614688	6
270	Choosing a genome editing strategy and target site. **2021**, 21-39	
269	Endogenous zebrafish proneural Cre drivers generated by CRISPR/Cas9 short homology directed targeted integration. **2021**, 11, 1732	3
268	Dynamics and competition of CRISPR-Cas9 ribonucleoproteins and AAV donor-mediated NHEJ, MMEJ and HDR editing. **2021**, 49, 969-985	19
267	Imaging Neuronal Signal Transduction Using Multiphoton FRET-FLIM. **2019**, 111-130	1
266	Applications of CRISPR-Cas in Ageing Research. **2020**, 213-230	1

265	Novel Advanced Nanomaterials and Devices for Nanoelectronics and Photonics. **2017**, 243-263	4
264	Efficient editing of OTC-deficient patient-derived primary human hepatocytes. **2020**, 2, 100065	8
263	CREATEd viruses go global. **2017**, 20, 1041-1042	2
262	Synthetic biology for improving cell fate decisions and tissue engineering outcomes. **2019**, 3, 631-643	5
261	CRISPR-Cas12a-assisted PCR tagging of mammalian genes. **2020**, 219,	19
260	Critical review on where CRISPR meets molecular diagnostics. **2021**, 3, 012001	11
259	Toward precise CRISPR DNA fragment editing and predictable 3D genome engineering. **2021**, 12, 828-856	1
258	High-efficiency nonhomologous insertion of a foreign gene into the herpes simplex virus genome. **2020**, 101, 982-996	5
257	Precision genome editing using synthesis-dependent repair of Cas9-induced DNA breaks.	1
256	Reprogramming human T cell function and specificity with non-viral genome targeting.	3
255	Exon 13-skipped USH2A protein retains functional integrity in mice, suggesting an exo-skipping therapeutic approach to treat USH2A-associated disease.	2
254	A Safe Harbor-Targeted CRISPR/Cas9 Homology Independent Targeted Integration (HITI) System for Multi-Modality Reporter Gene-Based Cell Tracking.	2
253	Fluorescent in vivo editing reporter (FIVER): A novel multispectral reporter of in vivo genome editing.	2
252	An Optimized CRISPR/Cas9 Approach for Precise Genome Editing in Neurons.	1
251	Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice.	0
250	Identification of Pre-Existing Adaptive Immunity to Cas9 Proteins in Humans.	58
249	In vivo CRISPR-Cas gene editing with no detectable genome-wide off-target mutations.	5
248	CRISPR-Cas12a-assisted PCR tagging of mammalian genes.	6

247	ORANGE: A CRISPR/Cas9-based genome editing toolbox for epitope tagging of endogenous proteins in neurons.	1
246	Highly efficient site-directed gene insertion in primary human natural killer cells using homologous recombination and CRISPaint delivered by AAV.	3
245	Pancreatic cancer cells assemble a CXCL12-keratin 19 coating to resist immunotherapy.	3
244	Deep profiling reveals substantial heterogeneity of integration outcomes in CRISPR knock-in experiments.	19
243	A most formidable arsenal: genetic technologies for building a better mouse. **2020**, 34, 1256-1286	10
242	Correction of muscular dystrophies by CRISPR gene editing. **2020**, 130, 2766-2776	25
241	CRISPR-based strategies for targeted transgene knock-in and gene correction. **2020**, 9, 20	1
240	CRISPR and Target-Specific DNA Endonucleases for Efficient DNA Knock-in in Eukaryotic Genomes. **2018**, 41, 943-952	16
239	Embryo-mediated genome editing for accelerated genetic improvement of livestock. **2020**, 7, 148	11
238	CRISPR Technology Challenge Facing the Numerical Integrity of Whole Human Genome DNA. **2017**, 1,	3
237	Pompe disease: pathogenesis, molecular genetics and diagnosis. **2020**, 12, 15856-15874	6
236	Gene editing of the extra domain A positive fibronectin in various tumors, amplified the effects of CRISPR/Cas system on the inhibition of tumor progression. **2017**, 8, 105020-105036	6
235	CRISPR-Cas9 HDR system enhances AQP1 gene expression. **2017**, 8, 111683-111696	7
234	The transformational impact of site-specific DNA modifiers on biomedicine and agriculture. **2018**, 15, 171-179	1
233	genome editing thrives with diversified CRISPR technologies. **2018**, 39, 58-71	8
232	Gene editing enables T-cell engineering to redirect antigen specificity for potent tumor rejection. **2019**, 2,	15
231	Quinidine Trial in a Patient with Epilepsy of Infancy with Migrating Focal Seizure and KCNT1 Mutation. **2017**, 25, 169-173	1
230	Multiplex Genome Editing in Chinese Hamster Ovary Cell Line Using All-in-One and HITI CRISPR Technology. **2021**, 11, 343-350	2

229	One-step efficient generation of dual-function conditional knockout and geno-tagging alleles in zebrafish. **2019**, 8,	14
228	Essential role for InSyn1 in dystroglycan complex integrity and cognitive behaviors in mice. **2019**, 8,	7
227	An efficient CRISPR-based strategy to insert small and large fragments of DNA using short homology arms. **2019**, 8,	41
226	Efficient targeted integration directed by short homology in zebrafish and mammalian cells. **2020**, 9,	34
225	Enhancement of homology-directed repair with chromatin donor templates in cells. **2020**, 9,	13
224	Genetically engineered birds; pre-CRISPR and CRISPR era. **2021**,	
223	The Role of Long Non-coding RNAs in Human Imprinting Disorders: Prospective Therapeutic Targets. **2021**, 9, 730014	2
222	Heading towards a dead end: The role of DND1 in germ line differentiation of human iPSCs. **2021**, 16, e0258427	0
221	Gene Therapy in Inherited Retinal Diseases: An Update on Current State of the Art. **2021**, 8, 750586	3
220	Recent Advances in CRISPR/Cas9-Based Genome Editing Tools for Cardiac Diseases. **2021**, 22,	0
219	Moderate the MAOA-L Allele Expression with CRISPR/Cas9 System.	
218	Targeting repair pathways with small molecules increases precise genome editing in pluripotent stem cells.	
217	Alexander Disease:A Guide for Patients and Families. **2017**, 4, i-96	0
216	Engineering of Human-Induced Pluripotent Stem Cells for Precise Disease Modeling. **2018**, 369-411	
215	Visual prostheses, optogenetics, stem cell and gene therapies: splitting the cake. **2018**, 13, 805-806	2
214	All-in-One Adeno-associated Virus Delivery and Genome Editing by Neisseria meningitidis Cas9 in vivo.	
213	New human chromosomal safe harbor sites for genome engineering with CRISPR/Cas9, TAL effector and homing endonucleases.	2
212	Scalable tagging of endogenous genes by homology-independent intron targeting.	

211	In vivo CRISPRa decreases seizures and rescues cognitive deficits in a rodent model of epilepsy.	0
210	Clinical Genetics of Vitelliform Macular Dystrophy: An Asian Perspective. **2019**, 255-271	
209	CHAPTER 17:CRISPR-based Technologies for Genome Engineering: Properties, Current Improvements and Applications in Medicine. **2019**, 400-433	1
208	Single AAV-mediated scarless genome editing in dysfunctional retinal neurons mediates robust visual restoration in mice.	0
207	A simple and efficient CRISPR technique for protein tagging.	
206	Fast and cloning-free CRISPR/Cas9-mediated genomic editing in mammalian cells.	1
205	Gene knock-ins in Drosophila using homology-independent insertion of universal donor plasmids.	2
204	The histone chaperone FACT induces Cas9 multi-turnover behavior and modifies genome manipulation in human cells.	
203	An efficient CRISPR-based strategy to insert small and large fragments of DNA using short homology arms.	
202	Direct readout of neural stem cell transgenesis with an integration-coupled gene expression switch.	
201	Systematic detection of Mendelian and non-Mendelian variants associated with retinitis pigmentosa by genome-wide association study.	
200	A Homology Independent Sequence Replacement Strategy in Human Cells Using a CRISPR Nuclease.	
199	An improved CRISPR/dCas9 interference tool for neuronal gene suppression.	0
198	Harnessing endogenous repair mechanisms for targeted gene knock-in of bovine embryos.	
197	Endogenous zebrafish proneural Cre drivers generated by CRISPR/Cas9 short homology directed targeted integration.	
196	Baculovirus-vectored precision delivery of large DNA cargoes in human genomes.	
195	Knock-in of labeled proteins into 5′UTR enables highly efficient generation of stable cell lines.	
194	Progress in Gene Editing Tools and Their Potential for Correcting Mutations Underlying Hearing and Vision Loss. **2021**, 3, 737632	4

193	Drag-and-drop genome insertion without DNA cleavage with CRISPR-directed integrases.	6
192	Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo. **2021**, 12, 6267	5
191	Fast and efficient generation of knock-in human organoids using homology-independent CRISPR/Cas9 precision genome editing.	0
190	Efficient replacement of long DNA fragments via non-homologous end joining at non-doding regions.	
189	Chromatin remodeler Arid1a regulates subplate neuron identity and wiring of cortical connectivity.	
188	High-fidelity, efficient, and reversible labeling of endogenous proteins using CRISPR-based designer exon insertion.	0
187	Homology-directed repair in mouse cells increased by CasRx-mediated knockdown or co-expressing Kaposi's sarcoma-associated herpesvirus ORF52. **2019**, 39,	2
186	RPE and Gene Therapy. **2020**, 265-279	
185	Correlative Ultrastructural Analysis of Functionally Modulated Synapses Using Automated Tape-Collecting Ultramicrotome and SEM Array Tomography. **2020**, 121-149	
184	Retinal Gene Therapy. **2020**, 487-515	
183	Successful Correction of ALD Patient-derived iPSCs Using CRISPR/Cas9.	
182	Programmable large DNA deletion, replacement, integration, and inversion with twin prime editing and site-specific recombinases.	1
181	Molecular classification of zebrafish retinal ganglion cells links genes to cell types to behavior.	3
180	Cas9 fusions for precision in vivo editing.	2
179	Single cell transcriptome analysis defines heterogeneity of the murine pancreatic ductal tree.	
178	Template-independent genome editing and repairing correct frameshift disease in vivo.	
177	The Application of CRISPR/Cas9 for the Treatment of Retinal Diseases. **2017**, 90, 533-541	13
176	Gene Therapy, Diet and Drug Approaches to Treating Inherited Retinal Disease. **2021**,	

175	CRISPR-Cas Technology: Emerging Applications in Clinical Microbiology and Infectious Diseases. **2021**, 14,	2
174	A cis-acting mechanism mediates transcriptional memory at Polycomb target genes in mammals. **2021**, 53, 1686-1697	2
173	Distinct in vivo dynamics of excitatory synapses onto cortical pyramidal neurons and parvalbumin-positive interneurons. **2021**, 37, 109972	0
172	Modulating CRISPR/Cas9 genome-editing activity by small molecules. **2021**,	1
171	Inherited retinal diseases: Linking genes, disease-causing variants, and relevant therapeutic modalities. **2021**, 101029	6
170	Find and cut-and-transfer (FiCAT) mammalian genome engineering. **2021**, 12, 7071	2
169	Multiplex labeling and manipulation of endogenous neuronal proteins using sequential CRISPR/Cas9 gene editing.	0
168	Rejuvenation of Tissue Stem Cells by Intrinsic and Extrinsic Factors.. **2022**, 11, 231-238	0
167	Designer organs: The future of personalized transplantation.. **2022**, 46, 180-190	0
166	Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges.. **2022**, 342, 345-361	7
165	CRISPR/Cas9 Ribonucleoprotein-Mediated Genome and Epigenome Editing in Mammalian Cells.. **2021**, 114087	1
164	A comparison of DNA repair pathways to achieve a site-specific gene modification of the Bruton's tyrosine kinase gene.. **2022**, 27, 505-516	0
163	Gene knock-out chain reaction enables high disruption efficiency of HPV18 / genes in cervical cancer cells.. **2022**, 24, 171-179	3
162	Efficient and error-free fluorescent gene tagging in human organoids without double-strand DNA cleavage.. **2022**, 20, e3001527	1
161	The CRISPR-Cas toolbox and gene editing technologies.. **2021**,	15
160	AAV-mediated gene editing lights up the lung.. **2021**,	0
159	Towards a Comprehensive Optical Connectome at Single Synapse Resolution Expansion Microscopy.. **2021**, 13, 754814	1
158	AAV11 permits efficient retrograde targeting of projection neurons.	2

157	An effective double gene knock-in strategy using small-molecule L755507 in the medaka fish (Oryzias latipes).. **2022**, e23465	
156	CRISPR-based genome editing through the lens of DNA repair.. **2022**, 82, 348-388	5
155	Carcinomas assemble a filamentous CXCL12-keratin-19 coating that suppresses T cell-mediated immune attack.. **2022**, 119,	1
154	Genome-wide detection of CRISPR editing in vivo using GUIDE-tag.. **2022**, 13, 437	1
153	Strategies to overcome the side effects of chimeric antigen receptor T cell therapy.. **2022**,	
152	Breasi-CRISPR: an efficient genome editing method to interrogate protein localization and protein-protein interactions in the embryonic mouse cortex.	1
151	Vitelliform Macular Dystrophy. **2022**, 125-149	
150	Retinitis Pigmentosa. **2022**, 69-97	
149	CRISPR Therapeutics for Duchenne Muscular Dystrophy.. **2022**, 23,	2
148	Reactivation of □globin expression using a minicircle DNA system to treat □thalassemia.. **2022**, 820, 146289	2
147	Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing. **2021**,	18
146	Dissecting chicken germ cell dynamics by combining a germ cell tracing transgenic chicken model with single-cell RNA sequencing.. **2022**, 20, 1654-1669	4
145	Efficient targeted insertion of large DNA fragments without DNA donors.. **2022**,	2
144	Treating Cardiovascular Disease with Liver Genome Engineering.. **2022**, 24, 75	
143	DNA Repair Pathways in the Context of Therapeutic Genome Editing. **2022**, 177-192	
142	Historical Overview of Genome Editing from Bacteria to Higher Eukaryotes. **2022**, 9-17	
141	Transposase-CRISPR mediated targeted integration (TransCRISTI) in the human genome.. **2022**, 12, 3390	0
140	CRISPR-Cas9 gene editing induced complex on-target outcomes in human cells.. **2022**,	0

139	Harnessing DSB repair to promote efficient homology-dependent and -independent prime editing.. **2022**, 13, 1240	0
138	Target residence of Cas9: challenges and opportunities in genome editing. **2022**, 3, 57-69	
137	Targeted Gene Insertion for Functional CFTR Restoration in Airway Epithelium.. **2022**, 4, 847645	
136	Carrier strategies boost the application of CRISPR/Cas system in gene therapy. 20210081	3
135	Seamless Gene Correction in the Human Cystic Fibrosis Transmembrane Conductance Regulator Locus by Vector Replacement and Vector Insertion Events.. **2022**, 4, 843885	
134	From DNA break repair pathways to CRISPR/Cas-mediated gene knock-in methods.. **2022**, 120409	1
133	CRISPR/Cas proteins are secreted virulence factors that trigger cellular immune responses. **2021**, 12, 3032-3044	1
132	Enhancing targeted transgene knock-in by donor recruitment. **2021**, e13163	1
131	Therapeutic Applications of CRISPR/Cas9 Technology for Infectious Diseases. **2022**, 557-573	
130	Therapeutic homology-independent targeted integration in retina and liver.. **2022**, 13, 1963	0
129	Nano-vectors for CRISPR/Cas9-mediated genome editing. **2022**, 44, 101482	2
128	Data_Sheet_1.DOCX. **2020**,	
127	Table_1.XLSX. **2020**,	
126	Image_1.JPEG. **2018**,	
125	Image_2.JPEG. **2018**,	
124	Table_1.DOC. **2018**,	
123	Image_1.pdf. **2018**,	
122	Retinitis Pigmentosa: Progress in Molecular Pathology and Biotherapeutical Strategies.. **2022**, 23,	2

121	Gene-independent therapeutic interventions to maintain and restore light sensitivity in degenerating photoreceptors.. **2022**, 101065		1
120	Mitochondrial base editor induces substantial nuclear off-target mutations.. *Nature*, **2022**,	50.4	5
119	New Editing Tools for Gene Therapy in Inherited Retinal Dystrophies.. **2022**,		1
118	Gelatin nanofiber mats with Lipofectamine/plasmid DNA complexes for in vitro genome editing.. **2022**, 216, 112561		0
117	From Bench to Bed: The Current Genome Editing Therapies for Glaucoma. **2022**, 10,		0
116	Production of AAVs and Injection into the Spinal Cord. **2022**, 375-415		
115	Gene Therapy for Acquired and Genetic Cholestasis. **2022**, 10, 1238		1
114	The origin of unwanted editing byproducts in gene editing. **2022**,		0
113	Identification of the CKM Gene as a Potential Muscle-Specific Safe Harbor Locus in Pig Genome. **2022**, 13, 921		0
112	CRISPR-Cas-Based Gene Therapy to Target Viral Infections. **2022**, 85-125		0
111	Plasticity-induced actin polymerization in the dendritic shaft regulates intracellular AMPA receptor trafficking.		
110	Speciation and adaptation research meets genome editing. **2022**, 377,		0
109	INSERT-seq enables high resolution mapping of genomically integrated DNA using nanopore sequencing.		1
108	Gene therapy to terminate tachyarrhythmias.		
107	Establishment of mouse model of inherited PIGO deficiency and therapeutic potential of AAV-based gene therapy. **2022**, 13,		0
106	Tools for Efficient Genome Editing; ZFN, TALEN, and CRISPR. **2022**, 29-46		2
105	Small-molecule enhancers of CRISPR-induced homology-directed repair in gene therapy: A medicinal chemist□ perspective. **2022**,		
104	Long-term correction of haemophilia B through CRISPR/Cas9 induced homology-independent targeted integration. **2022**,		1

103	CRISPR Modeling and Correction of Cardiovascular Disease. **2022**, 130, 1827-1850	4
102	Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV. **2022**, 2, 100236	3
101	A novel dual-targeting delivery system for specific delivery of CRISPR/Cas9 using hyaluronic acid, chitosan and AS1411. **2022**, 292, 119691	0
100	Protocol to study sufficiency of cis-regulatory elements in mouse embryonic stem cells using a CRISPR-mediated knockin approach. **2022**, 3, 101492	
99	Template-independent genome editing in the Pcdh15 mouse, a model of human DFNB23 nonsyndromic deafness. **2022**, 40, 111061	1
98	Massively targeted evaluation of therapeutic CRISPR off-targets in cells. **2022**, 13,	1
97	Large-scale genome editing based on high-capacity adenovectors and CRISPR-Cas9 nucleases rescues full-length dystrophin synthesis in DMD muscle cells.	0
96	Highly efficient CRISPR-mediated large DNA docking and multiplexed prime editing using a single baculovirus.	3
95	Duplex Labeling and Manipulation of Neuronal Proteins Using Sequential CRISPR/Cas9 Gene Editing. ENEURO.0056-22.2022	0
94	Gene Editing and Rett Syndrome: Does It Make the Cut?.	
93	Advance trends in targeting homology-directed repair for accurate gene editing: An inclusive review of small molecules and modified CRISPR-Cas9 systems. **2022**, 12, 371-391	1
92	From Bench to Bedside Delivering Gene Therapy for Leber Hereditary Optic Neuropathy. **2022**, 12, a041282	0
91	Reprogramming of Human B Cells from Secreting IgG to IgM by Genome Editing.	
90	CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies.	0
89	The application and progression of CRISPR/Cas9 technology in ophthalmological diseases.	
88	Breasi-CRISPR: an efficient genome editing method to interrogate protein localization and protein-protein interactions in the embryonic mouse cortex.	0
87	PIWI-Interacting RNA (piRNA) and Epigenetic Editing in Environmental Health Sciences.	1
86	Genome editing-mediated knock-in of therapeutic genes ameliorates the disease phenotype in a model of hemophilia. **2022**, 29, 551-562	1

85	Genetics behind Cerebral Disease with Ocular Comorbidity: Finding Parallels between the Brain and Eye Molecular Pathology. **2022**, 23, 9707	0
84	Modifying organs with gene therapy and gene modulation in the age of machine perfusion. **2022**, 27, 474-480	0
83	Nonviral Delivery of CRISPR/Cas Systems in mRNA Format. 2200082	0
82	CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives. **2022**, 11, 2964	0
81	Precision genome editing in the eye. **2022**, 119,	1
80	Deciphering spatial protein-protein interactions in brain using proximity labeling. **2022**, 100422	0
79	Generation of genetically engineered mice for lung cancer with mutant EGFR. **2022**, 632, 85-91	0
78	Automated identification of sequence-tailored Cas9 proteins using massive metagenomic data. **2022**, 13,	0
77	INSERT-seq enables high-resolution mapping of genomically integrated DNA using Nanopore sequencing. **2022**, 23,	0
76	The Power of Gene Technologies: 1001 Ways to Create a Cell Model. **2022**, 11, 3235	0
75	In vivo application of base and prime editing to treat inherited retinal diseases. **2022**, 101132	0
74	Development of an in vivo cleavable donor plasmid for targeted transgene integration by CRISPR-Cas9 and CRISPR-Cas12a. **2022**, 12,	0
73	Efficient and rapid fluorescent protein knock-in with universal donors in mammalian stem cells.	0
72	Implications of Neural Plasticity in Retinal Prosthesis. **2022**, 63, 11	1
71	Gene therapy for cystic fibrosis: Challenges and prospects. 13,	1
70	Real-time imaging of RNA polymerase I activity in living human cells. **2023**, 222,	0
69	Gene regulatory and gene editing tools and their applications for retinal diseases and neuroprotection: From proof-of-concept to clinical trial. 16,	0
68	Therapeutic modulation of gene expression in the disease state: Treatment strategies and approaches for the development of next-generation of the epigenetic drugs. 10,	0

67	A New Strategy for Increasing Knock-in Efficiency: Multiple Elongase and Desaturase Transgenes Knock-in by Targeting Long Repeated Sequences.	0
66	In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications. **2022**, 291, 121876	1
65	Challenges and opportunities in gene editing of B cells. **2022**, 206, 115285	0
64	Sequential verification of exogenous protein production in OVA gene-targeted chicken bioreactors. **2023**, 102, 102247	1
63	Prime editing for precise and highly versatile genome manipulation.	3
62	Gelatin-Based Electrospun Nanofibers Cross-Linked Using Horseradish Peroxidase for Plasmid DNA Delivery. **2022**, 12, 1638	1
61	An Optimized Enzyme-Nucleobase Pair Enables In Vivo RNA Metabolic Labeling with Improved Cell-Specificity.	1
60	Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses. **2022**, 191, 114616	0
59	From nuclease-based gene knock-in to prime editing promising technologies of precision gene engineering. **2022**, 3-4, 100017	0
58	Cas9-mediated tagging of endogenous loci using HITAG.	0
57	Applications and challenges for CRISPR/Cas9-mediated gene editing. **2022**,	0
56	CRISPR-Cas12a induced DNA double-strand breaks are repaired by multiple pathways with different mutation profiles in Magnaporthe oryzae. **2022**, 13,	2
55	Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases.	2
54	Low-dose AAV-CRISPR-mediated liver-specific knock-in restored hemostasis in neonatal hemophilia B mice with subtle antibody response. **2022**, 13,	0
53	Efficient single copy integration via homology-directed repair (scHDR) by 5?modification of large DNA donor fragments in mice.	0
52	Superior Fidelity and Distinct Editing Outcomes of SaCas9 Compared to SpCas9 in Genome Editing. **2022**,	0
51	Potential therapeutic strategies for photoreceptor degeneration: the path to restore vision. **2022**, 20,	1
50	Genome Editing and Pathological Cardiac Hypertrophy. **2023**, 87-101	0

49	Nanoparticles-mediated CRISPR-Cas9 gene therapy in inherited retinal diseases: applications, challenges, and emerging opportunities. **2022**, 20,	3
48	Highly Efficient One-Step Tagging of Endogenous Genes in Primary Cells Using CRISPR-Cas Ribonucleoproteins. **2022**, 5, 843-853	0
47	Simultaneous inhibition of DNA-PK and Pol? improves integration efficiency and precision of genome editing.	0
46	A Tet-Inducible CRISPR Platform for High-Fidelity Editing of Human Pluripotent Stem Cells. **2022**, 13, 2363	0
45	Gene therapy for liver diseases progress and challenges.	0
44	MDM2 antagonists promote CRISPR/Cas9-mediated precise genome editing in sheep primary cells. **2023**,	0
43	CRISPR-interceded CHO cell line development approaches.	0
42	Future Directions for Adrenal Insufficiency: Cellular Transplantation and Genetic Therapies.	0
41	CRISPR/Cas9-based genome editing for multimodal synergistic cancer nanotherapy. **2023**, 48, 101734	0
40	TAxI-peptide targeted Cas12a ribonuclease protein nanoformulations increase genome editing in hippocampal neurons. **2023**, 354, 188-195	0
39	Nucleic acid nanostructure for delivery of CRISPR/Cas9-based gene editing system.	0
38	Viruses for Systemic Delivery. **2023**, 125-152	0
37	Nonviral Ex Vivo Genome Editing in Mouse Bona Fide Hematopoietic Stem Cells with CRISPR/Cas9. **2023**, 213-221	0
36	KIF1A-Associated Neurological Disorder: An Overview of a Rare Mutational Disease. **2023**, 16, 147	0
35	Marine-Derived Natural Product HDYL-GQQ-495 Targets P62 to Inhibit Autophagy. **2023**, 21, 68	0
34	PASTE: The Way Forward for Large DNA Insertions.	1
33	GEARBOCS: An Adeno Associated Virus Tool forIn VivoGene Editing in Astrocytes.	0
32	A Comprehensive Review of Dilated Cardiomyopathy in Pre-clinical Animal Models in Addition to Herbal Treatment Options and Multi-modality Imaging Strategies. **2022**, 22, 207-225	0

31	Genome Editing Using CRISPR. **2023**, 1-26	0
30	Gene Therapy for Paediatric Homozygous Familial Hypercholesterolaemia. **2023**,	0
29	Improving recombinant protein production in CHO cells using the CRISPR-Cas system. **2023**, 64, 108115	0
28	New advancements in CRISPR based gene therapy of Duchenne muscular dystrophy. **2023**, 867, 147358	0
27	Genome editing, a superior therapy for inherited retinal diseases. **2023**, 206, 108192	0
26	Precise homology-directed installation of large genomic edits in human cells with cleaving and nicking high-specificity Cas9 variants.	0
25	Viral Vectors, Exosomes, and Vexosomes: Potential Armamentarium for Delivering CRISPR/Cas to Cancer Cells. **2023**, 115555	0
24	Unique progerin C-terminal peptide ameliorates Hutchinson□ilford progeria syndrome phenotype by rescuing BUBR1. **2023**, 3, 185-201	0
23	Increased On-Target Rate and Risk of Concatemerization after CRISPR-Enhanced Targeting in ES Cells. **2023**, 14, 401	0
22	Lipid nanoparticle-based ribonucleoprotein delivery for in vivo genome editing. **2023**, 355, 406-416	0
21	Delivery challenges for CRISPR□as9 genome editing for Duchenne muscular dystrophy. **2023**, 4, 011307	0
20	In search of an ideal template for therapeutic genome editing: A review of current developments for structure optimization. 5,	0
19	Applications of CRISPR/Cas9 in the field of microbiology. **2023**,	0
18	Silk-Gel Powered Adenoviral Vector Enables Robust Genome Editing of PD-L1 to Augment Immunotherapy across Multiple Tumor Models. 2206399	0
17	Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy.	0
16	A CRISPR/Cas-Based Method for Precise DNA Integration in Xenopus laevis Oocytes Followed by Intracytoplasmic Sperm Injection (ICSI) Fertilization. **2023**, 131-143	0
15	Long-read sequence analysis of MMEJ-mediated CRISPR genome editing reveals complex on-target vector insertions that may escape standard PCR-based quality control.	0
14	Antibody-directed extracellular proximity biotinylation reveals Contactin-1 regulates axo-axonic innervation of axon initial segments.	0

13	Implementation of ubiquitous chromatin opening elements as artificial integration sites for CRISPR/Cas9-mediated knock-in in mammalian cells. **2023**, 23,	0
12	Shaping the future from the small scale: dry powder inhalation of CRISPR-Cas9 lipid nanoparticles for the treatment of lung diseases. 1-17	0
11	Genome-engineering technologies for modeling and treatment of cystic fibrosis. **2023**, 68, 111-120	0
10	Establishment, optimization, and application of genetic technology in Aspergillus spp.. 14,	0
9	One-step generation of auxin-inducible degron cells with high-efficiency homozygous tagging.	0
8	CRISPR-mediated optogene expression from a cell-specific endogenous promoter in retinal ON-bipolar cells to restore vision. 3,	0
7	A CRISPR/Cas9-Based Assay for High-Throughput Studies of Cancer-Induced Innervation. **2023**, 15, 2026	0
6	Gene Editing in Mouse Zygotes Using the CRISPR/Cas9 System. **2023**, 207-230	0
5	Mutation-independent gene knock-in therapy targeting 5?UTR for autosomal dominant retinitis pigmentosa. **2023**, 8,	0
4	Gene therapy for urea cycle defects: An update from historical perspectives to future prospects.	0
3	Therapeutic strategy for spinal muscular atrophy by combining gene supplementation and genome editing.	0
2	High-efficiency and multilocus targeted integration in CHO cells using CRISPR-mediated donor nicking and DNA repair inhibitors.	0
1	CRISPR-EDITING THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY.	0